Cargando…
Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities
There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...
Autores principales: | Medhora, Meetha, Phadnis, Preeya, Narayanan, Jayashree, Gasperetti, Tracy, Zielonka, Jacek, Moulder, John E., Fish, Brian L., Szabo, Aniko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111401/ https://www.ncbi.nlm.nih.gov/pubmed/33986677 http://dx.doi.org/10.3389/fphar.2021.646076 |
Ejemplares similares
-
Wound Trauma Exacerbates Acute, but not Delayed, Effects of Radiation in Rats: Mitigation by Lisinopril
por: Medhora, Meetha, et al.
Publicado: (2020) -
Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes
por: Gasperetti, Tracy, et al.
Publicado: (2021) -
Lisinopril Mitigates Radiation-Induced Mitochondrial Defects in Rat Heart and Blood Cells
por: Ortiz de Choudens, Saryleine, et al.
Publicado: (2022) -
Corrigendum: Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes
por: Gasperetti, Tracy, et al.
Publicado: (2021) -
Dose-modifying factor for captopril for mitigation of radiation injury to normal lung
por: Medhora, Meetha, et al.
Publicado: (2012)